GSK, Vir Use CRISPR, Artificial Intelligence to Find COVID-19 Cure

PharmaNewsIntelligence | April 07, 2020

GSK, Vir Use CRISPR, Artificial Intelligence to Find COVID-19 Cure
GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the development of specific antibody candidates using Vir’s monoclonal antibody platform technology and GSK’s expertise in functional genomics. Vir’s platforms, VIR-7831 and VIR-7832, have already shown a similarity for the SARS-CoV-2 spike protein and researchers believe they show great potential to neutralize the SARS-CoV-2 sequence.

Spotlight

Each year, in recognition of Girls’ Day in Austria, Sandoz invites young women to its Anti-Infectives site in Kundl, Austria, where they have the opportunity to meet scientists and gain hands-on experience in Sandoz laboratories as well as in the technical areas of the pharmaceutical industry.

Related News

PHARMACY MARKET

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Everest Medicines | September 23, 2021

AbCellera and Everest Medicines Limited announced that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest’s portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology. We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, We believe our full-stack discovery engine, combined with Everest’s clinical development capabilities, creates synergy and the opportunity to speed the delivery of therapies to patients around the world. - Carl Hansen, Ph.D., CEO and President of AbCellera. By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access. The collaboration will leverage the full breadth of AbCellera’s technology stack, including sourcing fully humanized antibodies from the Trianni Mouse®, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform. This collaboration will allow us to gain access to AbCellera’s cutting edge, AI-powered antibody discovery platform, which will greatly accelerate and increase the efficiency of our internal discovery efforts. - Jennifer Yang, Ph.D., Chief Scientific Officer of Everest Medicines. Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations in Asia and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of ten potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. About AbCellera Biologics Inc. AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. AbCellera Forward-looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

Read More

Hemogenyx Pharmaceuticals plc signed Biological Investigation and Material Supply Agreement with Eli Lilly

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engaged in the research, development, manufacture and marketing of human pharmaceutical and veterinary products. Under the Agreement, Lilly will supply the Company with certain biological materials and related confidential information in order for Company to perform research and development activities aimed at the discovery and validation of novel materials ("Materials") to be used for the treatment of systemic lupus erythematosus ("Lupus") and possibly other autoimmune diseases.

Read More

PHARMACY MARKET

Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regulatory approvals to execute phase 3 and has recruited leading uveitis experts as principal investigators. Tarsier plans to enroll the first patient in Q4 of 2021. Tarsier's technology, TRS, is a novel immunomodulator molecule that showed, in a dose-ranging, randomized, double-masked phase I\II trial in the target indication, a prompt and statistically significant improvement in signs and symptoms of uveitis. "We are excited to have the support of our existing and new investors, as we continue our clinical development of TRS01 in advanced stages," said Dr. Haim Langford, CEO of Tarsier. "Looking ahead, we are eager to bring our lead product to market and simultaneously progress our development of important pipeline projects for other back-of -the-eye blinding diseases, and plan to raise additional capital to realize these as well." About Tarsier Pharma Tarsier Pharma is a late clinical stage pharmaceutical company, phase-3 ready, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a breakthrough proprietary technology platform, based on a new bio-inspired chemical entity, with novel mechanism of action and demonstrated safety and efficacy in a rare debilitating and blinding indication. Lead product candidate for uveitic glaucoma Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier's TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided, due to their negative side effects in expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma.

Read More

Spotlight

Each year, in recognition of Girls’ Day in Austria, Sandoz invites young women to its Anti-Infectives site in Kundl, Austria, where they have the opportunity to meet scientists and gain hands-on experience in Sandoz laboratories as well as in the technical areas of the pharmaceutical industry.